No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(s)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo |
- |
- |
- |
- |
1件: 284 |
2 |
(s)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide |
Magnesium hydroxide |
D00731 |
- |
- |
1件: 284 |
3 |
(s)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m |
- |
- |
- |
- |
1件: 284 |
4 |
(s)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide |
Magnesium hydroxide |
D00731 |
- |
- |
1件: 284 |
5 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
6 |
Alefacept |
Alefacept |
D02800 |
1件: CD58 |
2件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection |
6件: 37, 60, 65, 164, 284, 285 |
7 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
13件: 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
8 |
Alpha beta depletion |
- |
- |
- |
- |
2件: 60, 284 |
9 |
Anti-thymocyte globulin |
- |
- |
- |
- |
18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
10 |
Antithymocyte globulin |
- |
- |
- |
- |
3件: 60, 65, 284 |
11 |
Bpx-501 t cells |
- |
- |
- |
- |
4件: 65, 284, 285, 326 |
12 |
Busulfan |
Busulfan |
D00248 |
- |
- |
13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
13 |
Busulfan, cyclophosphamide, atg, gcsf |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 65, 284 |
14 |
Busulfan, fludarabine, atg, tli |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
2件: 65, 284 |
15 |
Campath, fludarabine, cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 65, 284 |
16 |
Cd3/cd19 depleted leukocytes |
- |
- |
- |
- |
1件: 284 |
17 |
Cd34 stem cell selection therapy |
- |
- |
- |
- |
3件: 60, 65, 284 |
18 |
Cd45ra depleted leukocytes |
- |
- |
- |
- |
1件: 284 |
19 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
20 |
Cyclophosphamide dose level 1 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 65, 284 |
21 |
Cyclophosphamide dose level 2 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 65, 284 |
22 |
Cyclophosphamide dose level 3 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 65, 284 |
23 |
Cyclophosphamide dose level 4 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 65, 284 |
24 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
25 |
Daclizumab |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
7件: 13, 56, 60, 65, 97, 283, 284 |
26 |
Deferasirox |
Deferasirox |
D03669 |
- |
- |
3件: 254, 284, 286 |
27 |
Deferitazole |
Deferitazole |
D10388 |
- |
- |
1件: 284 |
28 |
Deferoxamine |
Deferoxamine |
D01186, D03670 |
- |
- |
2件: 284, 286 |
29 |
Desferal |
Deferoxamine |
D01186, D03670 |
- |
- |
2件: 284, 286 |
30 |
Enriched hematopoetic stem cell infusion |
- |
- |
- |
- |
3件: 13, 19, 284 |
31 |
Exjade |
Deferasirox |
D03669 |
- |
- |
3件: 254, 284, 286 |
32 |
Fbs0701 |
- |
- |
- |
- |
1件: 284 |
33 |
Fbs0701 capsule |
- |
- |
- |
- |
1件: 284 |
34 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
35 |
Fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
36 |
Fludarabine monophosphate |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
4件: 49, 65, 284, 326 |
37 |
Fludarabine phosphate |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
11件: 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 |
38 |
G-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
12件: 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
39 |
Gcsf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
3件: 36, 65, 284 |
40 |
Human placental derived stem cell |
- |
- |
- |
- |
4件: 19, 20, 60, 284 |
41 |
Hydroxide |
Hydroxide ion |
- |
- |
- |
4件: 46, 96, 97, 284 |
42 |
Hydroxyurea |
Hydroxyurea |
D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
43 |
Icl670 |
Deferasirox |
D03669 |
- |
- |
2件: 284, 286 |
44 |
Iron |
Iron |
- |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
45 |
Iron chelating agents |
Iron |
- |
- |
- |
1件: 284 |
46 |
L-leucine |
L-leucine |
D00030 |
- |
- |
1件: 284 |
47 |
Lenalidomide |
Lenalidomide |
D04687 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
7件: 16, 26, 28, 34, 49, 284, 300 |
48 |
Leucine |
L-leucine |
D00030 |
- |
- |
7件: 5, 6, 7, 127, 283, 284, 299 |
49 |
Magnesium |
Magnesium |
- |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
50 |
Magnesium hydroxide |
Magnesium hydroxide |
D00731 |
- |
- |
1件: 284 |
51 |
Melphalan |
Melphalan |
D00369 |
- |
- |
14件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
52 |
Mesenchymal stromal cells |
- |
- |
- |
- |
6件: 36, 51, 96, 97, 274, 284 |
53 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
54 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
55 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
56 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
57 |
Myeloablative preparative regimen |
- |
- |
- |
- |
3件: 62, 65, 284 |
58 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
59 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
60 |
Reduced intensity preparative regimen |
- |
- |
- |
- |
3件: 62, 65, 284 |
61 |
Reduced toxicity ablative regimen |
- |
- |
- |
- |
3件: 62, 65, 284 |
62 |
Rimiducid |
- |
- |
- |
- |
5件: 19, 65, 284, 285, 326 |
63 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
64 |
Rivogenlecleucel |
- |
- |
- |
- |
4件: 19, 65, 284, 285 |
65 |
Sotatercept |
Sotatercept |
D09670 |
1件: ACVR2A |
4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway |
2件: 86, 284 |
66 |
Sotatercept with prednisone boost |
Sotatercept |
D09670 |
1件: ACVR2A |
4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway |
1件: 284 |
67 |
Ssp-004184 100 mg |
- |
- |
- |
- |
1件: 284 |
68 |
Ssp-004184 100 mg capsule |
- |
- |
- |
- |
1件: 284 |
69 |
Ssp-004184 250 mg |
- |
- |
- |
- |
1件: 284 |
70 |
Ssp-004184 250 mg capsule |
- |
- |
- |
- |
1件: 284 |
71 |
Ssp-004184 375 mg |
- |
- |
- |
- |
1件: 284 |
72 |
Ssp-004184 375 mg capsule |
- |
- |
- |
- |
1件: 284 |
73 |
Ssp-004184 50 mg |
- |
- |
- |
- |
1件: 284 |
74 |
Ssp-004184 50 mg capsule |
- |
- |
- |
- |
1件: 284 |
75 |
Ssp-004184 500 mg |
- |
- |
- |
- |
1件: 284 |
76 |
Ssp-004184 500 mg capsule |
- |
- |
- |
- |
1件: 284 |
77 |
Ssp-004184aq 100 mg |
- |
- |
- |
- |
1件: 284 |
78 |
Ssp-004184aq 100 mg capsule |
- |
- |
- |
- |
1件: 284 |
79 |
Ssp-004184aq 200 mg |
- |
- |
- |
- |
1件: 284 |
80 |
Ssp-004184aq 200 mg capsule |
- |
- |
- |
- |
1件: 284 |
81 |
Ssp-004184aq 250 mg |
- |
- |
- |
- |
1件: 284 |
82 |
Ssp-004184aq 250 mg capsule |
- |
- |
- |
- |
1件: 284 |
83 |
Ssp-004184aq 375 mg |
- |
- |
- |
- |
1件: 284 |
84 |
Ssp-004184aq 375 mg capsule |
- |
- |
- |
- |
1件: 284 |
85 |
Ssp-004184aq 50 mg |
- |
- |
- |
- |
1件: 284 |
86 |
Ssp-004184aq 50 mg capsule |
- |
- |
- |
- |
1件: 284 |
87 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
88 |
Thiotepa |
Thiotepa |
D00583 |
- |
- |
11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
89 |
Thiotepa--escalated dose |
Thiotepa |
D00583 |
- |
- |
4件: 19, 20, 65, 284 |
90 |
Thiotepa--single daily dose |
Thiotepa |
D00583 |
- |
- |
4件: 19, 20, 65, 284 |
91 |
Trifluoperazine |
Trifluoperazine |
D00799, D01448, D08636 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 283, 284 |